Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.

Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H.

Schizophr Bull. 2014 Nov;40(6):1385-403. doi: 10.1093/schbul/sbu030. Review.

2.

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU.

CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. Review.

PMID:
22900950
3.

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

Maayan L, Vakhrusheva J, Correll CU.

Neuropsychopharmacology. 2010 Jun;35(7):1520-30. doi: 10.1038/npp.2010.21. Review.

4.

Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.

Mukundan A, Faulkner G, Cohn T, Remington G.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006629. doi: 10.1002/14651858.CD006629.pub2. Review.

PMID:
21154372
5.

[Effects of Topiramate for atypical antipsychotic-induced body weight gain and metabolic adversities: a systematic review and meta-analysis].

Liang H, Li H, Hu Y, Li S, Lü L, Song X.

Zhonghua Yi Xue Za Zhi. 2016 Jan 19;96(3):216-23. doi: 10.3760/cma.j.issn.0376-2491.2016.03.014. Review. Chinese.

PMID:
26879726
6.

Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials.

Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J.

J Clin Psychopharmacol. 2015 Oct;35(5):499-509. doi: 10.1097/JCP.0000000000000392.

PMID:
26280837
7.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
8.

Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study.

Wu RR, Jin H, Gao K, Twamley EW, Ou JJ, Shao P, Wang J, Guo XF, Davis JM, Chan PK, Zhao JP.

Am J Psychiatry. 2012 Aug;169(8):813-21. doi: 10.1176/appi.ajp.2012.11091432.

PMID:
22711171
9.

Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials.

Pringsheim T, Lam D, Ching H, Patten S.

Drug Saf. 2011 Aug 1;34(8):651-68. doi: 10.2165/11592020-000000000-00000. Review.

PMID:
21751826
10.

Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.

Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH.

JAMA. 2008 Jan 9;299(2):185-93. doi: 10.1001/jama.2007.56-b.

PMID:
18182600
11.

Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.

Ellinger LK, Ipema HJ, Stachnik JM.

Ann Pharmacother. 2010 Apr;44(4):668-79. doi: 10.1345/aph.1M550. Review.

PMID:
20233913
12.

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.

Narula PK, Rehan HS, Unni KE, Gupta N.

Schizophr Res. 2010 May;118(1-3):218-23. doi: 10.1016/j.schres.2010.02.001.

PMID:
20207521
13.
14.

Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.

de Silva VA, Dayabandara M, Wijesundara H, Henegama T, Gunewardena H, Suraweera C, Hanwella R.

J Psychopharmacol. 2015 Dec;29(12):1255-61. doi: 10.1177/0269881115613519.

PMID:
26510448
15.

Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.

Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, Golden LH, Lieberman JA, Stroup TS; METS Investigators..

Am J Psychiatry. 2013 Sep;170(9):1032-40. doi: 10.1176/appi.ajp.2013.12010127.

16.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. French.

PMID:
20620267
17.

Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.

Praharaj SK, Jana AK, Goyal N, Sinha VK.

Br J Clin Pharmacol. 2011 Mar;71(3):377-82. doi: 10.1111/j.1365-2125.2010.03783.x. Review.

18.

Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study.

Wang M, Tong JH, Zhu G, Liang GM, Yan HF, Wang XZ.

Schizophr Res. 2012 Jun;138(1):54-7. doi: 10.1016/j.schres.2012.02.021.

PMID:
22398127
19.

Aripiprazole in schizophrenia and schizoaffective disorder: A review.

Stip E, Tourjman V.

Clin Ther. 2010;32 Suppl 1:S3-20. doi: 10.1016/j.clinthera.2010.01.021. Review.

PMID:
20152550
20.

Metformin to reduce weight gain and metabolic disturbance in schizophrenia.

Faulkner G, Duncan M.

Evid Based Ment Health. 2015 Aug;18(3):89. doi: 10.1136/eb-2014-102039. No abstract available.

PMID:
26081916
Items per page

Supplemental Content

Support Center